Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Deutsche Boerse AG  >  Elanix Biotechnologies AG    ELN   DE000A0WMJQ4

ELANIX BIOTECHNOLOGIES AG

(ELN)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Elanix Biotechnologies AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/22/2019 | 04:20am EDT

DGAP Voting Rights Announcement: Elanix Biotechnologies AG
Elanix Biotechnologies AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

22.07.2019 / 10:17
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: Elanix Biotechnologies AG
Street: c/o Frankfurt, Hanauer Landstrasse 291 B (BC GmbH)
Postal code: 60314
City: Frankfurt am Main
Germany
Legal Entity Identifier (LEI): 391200SYNFFL0NPAJK90

2. Reason for notification
  Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
X Other reason:
Termination of the voting right agreement

3. Details of person subject to the notification obligation
Natural person (first name, surname): Anthony De Buys Rossingh
Date of birth: 22 Sep 1967

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
 

5. Date on which threshold was crossed or reached:
18 Dec 2018

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 1.76 % 0 % 1.76 % 8.080.902
Previous notification 19.35 % 0 % 19.35 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE000A0WMJQ4 142592 0 1.76 % 0 %
Total 142592 1.76 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
%
    Total %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
X Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
  Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
 

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
16 Jul 2019



22.07.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Elanix Biotechnologies AG
c/o Frankfurt, Hanauer Landstrasse 291 B (BC GmbH)
60314 Frankfurt am Main
Germany
Internet: www.elanixbiotechnologies.com

 
End of News DGAP News Service

826599  22.07.2019 

fncls.ssp?fn=show_t_gif&application_id=826599&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELANIX BIOTECHNOLOGIES AG
08/19ELANIX BIOTECHNOLOGIES AG : Preliminary announcement of the publication of finan..
EQ
07/26ELANIX BIOTECHNOLOGIES AG : Release according to Article 40, Section 1 of the Wp..
EQ
07/22ELANIX BIOTECHNOLOGIES AG : Release according to Article 40, Section 1 of the Wp..
EQ
06/25ELANIX BIOTECHNOLOGIES AG : Correction of a release from 20/06/2019 according to..
EQ
06/20ELANIX BIOTECHNOLOGIES AG : Release according to Article 40, Section 1 of the Wp..
EQ
05/13ELANIX BIOTECHNOLOGIES AG : Criminal charges have been filed against the former ..
EQ
04/1818-04-2019ELANIX BIOTECHNOLOGIES AG : Nomination of the chairman of the supervis..
PU
04/18ELANIX BIOTECHNOLOGIES AG : Nomination of the chairman of the supervisory board,..
EQ
2017ELANIX BIOTECHNOLOGIES AG : capital increase successfully placed, gross issuing ..
PU
2017ELANIX BIOTECHNOLOGIES : Release according to Article 26, Section 1 of the WpHG ..
PU
More news
Financials (EUR)
Sales 2018 -
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 -
Capi. / Sales2018 -
Capi. / Sales2019 -
Capitalization 10,9 M
Chart ELANIX BIOTECHNOLOGIES AG
Duration : Period :
Elanix Biotechnologies AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 1,35  €
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Tomas J. Svoboda Chief Executive Officer
Jürgen Ferdinand Kullmann Chairman-Supervisory Board
Egon Minar Chief Operating & Financial Officer
Abigael de Buys Roessingh Member-Supervisory Board
Marc Voigt Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
ELANIX BIOTECHNOLOGIES AG-1.46%12
IQVIA HOLDINGS INC34.91%30 701
LONZA GROUP36.75%26 363
INCYTE CORPORATION32.91%18 177
CELLTRION, INC.--.--%16 143
EXACT SCIENCES CORPORATION89.89%15 300